BioNTech SE

96.51
3.39 (3.64%)
At close: Apr 11, 2025, 3:59 PM
97.15
0.67%
After-hours: Apr 11, 2025, 07:57 PM EDT
3.64%
Bid 95.27
Market Cap 23.16B
Revenue (ttm) 2.74B
Net Income (ttm) -673.89M
EPS (ttm) -3.05
PE Ratio (ttm) -31.64
Forward PE -36.66
Analyst Buy
Ask 97.26
Volume 1,021,844
Avg. Volume (20D) 861,408
Open 93.70
Previous Close 93.12
Day's Range 92.11 - 97.08
52-Week Range 76.53 - 131.49
Beta 1.08

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2019
Employees 6,772
Stock Exchange NASDAQ
Ticker Symbol BNTX
Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $144, which is an increase of 49.21% from the latest price.

Stock Forecasts

Next Earnings Release

BioNTech SE is scheduled to release its earnings on May 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-1.18%
Shares of vaccine stocks are trading lower on repo... Unlock content with Pro Subscription
1 month ago
-6.61%
BioNTech shares are trading lower. Morgan Stanley and TD Cowen cut their respective price targets on the stock.